Bicara Therapeutics Inc.
BCAX Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$17.07
3.1%What Bicara Therapeutics Inc. does
No business description yet.
- Legal name
- Bicara Therapeutics Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Accession · CIK
- 0001628280-26-022010
0002023658
Revenue and margins
Bicara Therapeutics Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$107M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Bicara Therapeutics Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 225.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Bicara Therapeutics Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $230M | $490M | $415M |
| Current ratio | 15.3x | 27.9x | 14.6x |
| Quick ratio | 15.3x | 27.9x | 14.6x |
| Total assets | $234M | $510M | $431M |
| Total liabilities | $15.5M | $18.1M | $29.5M |
| Shareholders' equity | −$149M | $492M | $401M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✕ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −2.7% | 1.8% | −6.6% |
| Altman Z'' | −7.32 | 32.24 | 15.11 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $30.6M | $63.6M | — |
| Operating income | −$39.9M | −$82.4M | −$156M |
| Pretax income | −$52.0M | −$67.8M | −$138M |
| Income tax | $0.0M | $0.2M | $0.2M |
| Net income | −$52.0M | −$68.0M | −$138M |
| Diluted EPS | −$89.61 | −$4.05 | −$2.52 |
| Diluted shares | 0.58B | 16.81B | 54.68B |
| Cash flow | |||
| Cash from operations | −$45.6M | −$74.8M | −$107M |
| Capital expenditure | $0.6M | $0.1M | $0.3M |
| Free cash flow | −$46.2M | −$74.8M | −$107M |
| Depreciation and amortization | $0.0M | $0.1M | $0.1M |
| Stock-based compensation | $1.9M | $7.4M | $15.0M |
| Balance sheet | |||
| Cash and short-term investments | $230M | $490M | $415M |
| Current assets | $231M | $503M | $422M |
| Current liabilities | $15.1M | $18.0M | $28.9M |
| Property and equipment, net | $0.2M | $0.2M | $0.3M |
| Total assets | $234M | $510M | $431M |
| Total liabilities | $15.5M | $18.1M | $29.5M |
| Preferred stock | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | −$149M | $492M | $401M |
| Returns | |||
| Return on capital employed | −18.2% | −16.7% | −38.7% |
| Return on equity | — | −39.6% | −30.9% |
| Return on assets | −22.2% | −18.3% | −29.3% |
| Return on tangible equity | — | −13.8% | −34.4% |
| Growth | |||
| Share count change | — | 2,797.0% | 225.4% |
| Financial health | |||
| Current ratio | 15.3x | 27.9x | 14.6x |
| Quick ratio | 15.3x | 27.9x | 14.6x |
| Quality scores | |||
| Altman Z'' | −7.3 | 32.2 | 15.1 |
| Accruals ratio | −2.7% | 1.8% | −6.6% |
Source: SEC EDGAR XBRL filings (CIK 0002023658). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.